FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308394944> ?p ?o ?g. }

• W4308394944 abstract "<h3>Background</h3> Immune-related Adverse Events (irAEs) are rare but serious sequelae of treatment with immuno-oncology (IO) therapeutics. These therapeutics, including monoclonal antibodies targeting programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), have had transformative effects on outcomes for patients with advanced cancers. Although most patients tolerate the therapies well, a few experience irAEs ranging in severity up to life-threatening or fatal. These irAEs involve diverse organs including the heart, kidney, liver and lung, and gastrointestinal, musculoskeletal, central and peripheral nervous systems. Because of the relatively low incidence and wide variety of irAEs due to various immunotherapies for multiple tumor types, establishment of an efficient centralized repository for acquisition and organized distribution of well-annotated biospecimens is vital for translational studies that improve understanding of the molecular pathogenesis and treatment of these significant toxicities. <h3>Methods</h3> This multi-institutional study is open at sites across the National Clinical Trial Network. Patients may be pre-registered prior to starting IO therapy, or registered when they experience one or more irAEs. Any patient who has not previously been treated with CTLA-4, PD-1 or PD-L1 inhibitors is eligible for pre-registration. These patients provide blood and stool samples prior to starting IO therapy and again after 1 month. Regardless of whether they were pre-registered, patients who received ≥ 1 IO therapeutics (e.g., CTLA-4, PD-1 or PD-L1 inhibitor) and experienced 1) ≥ 1 grade 3–5 irAEs, 2) ≥ 1 grade 2 dermatologic or rheumatologic irAEs, 3) rare infection, or 4) tumor hyperprogression may be registered to the study. IrAEs of interest include myocarditis, colitis, hepatitis, nephritis, myositis, pneumonitis, meningitis/encephalitis, dermatitis, endocrinopathies, neuropathy, other rheumatological, hematologic cytopenias, and pancreatitis. Patients may be on an NCTN or non-NCTN IO trial or be receiving standard-of-care therapy. Registration must occur ≤ 96 hours after confirmation of the irAE. Clinical data are collected at registration, after 1 month after, and for up to 1 year. Biospecimens include archival tumor blocks, biopsies of inflammatory tissues used to establish irAE diagnosis, blood for isolation of plasma and peripheral blood mononuclear cells, and stool samples. Imaging data are collected for patients with hyperprogression, pneumonitis, or other radiographically-diagnosed irAEs. Accrual goal is 2000 pre-registered and 360 registered subjects. As of June 30, 2022, 485 sites have been approved to participate and 88 subjects have been registered. Biospecimens and data will be made available to investigators following future submission and approval of proposals. <h3>Acknowledgements</h3> U10CA180821, U10CA180882, U24CA196171; U10CA180899 (COG); U10CA180820 (ECOG-ACRIN); U10CA180888 (SWOG); U10CA180868 (NRG); https://acknowledgments.alliancefound.org <h3>Trial Registration</h3> ClinicalTrials. gov NCT04242095 <h3>Ethics Approval</h3> The study is approved by the National Cancer Institute Central Institutional Review Board." @default.
• W4308394944 created "2022-11-11" @default.
• W4308394944 creator A5000978986 @default.
• W4308394944 creator A5007239425 @default.
• W4308394944 creator A5017326158 @default.
• W4308394944 creator A5022594161 @default.
• W4308394944 creator A5026163032 @default.
• W4308394944 creator A5044586794 @default.
• W4308394944 creator A5044692746 @default.
• W4308394944 creator A5045824886 @default.
• W4308394944 creator A5054697421 @default.
• W4308394944 creator A5061064382 @default.
• W4308394944 creator A5073060840 @default.
• W4308394944 creator A5075890039 @default.
• W4308394944 creator A5077456327 @default.
• W4308394944 creator A5077959964 @default.
• W4308394944 date "2022-11-01" @default.
• W4308394944 modified "2023-10-01" @default.
• W4308394944 title "1244 Alliance A151804: Establishment of a national biorepository to advance studies of immune-related adverse events" @default.
• W4308394944 doi "https://doi.org/10.1136/jitc-2022-sitc2022.1244" @default.
• W4308394944 hasPublicationYear "2022" @default.
• W4308394944 type Work @default.
• W4308394944 citedByCount "0" @default.
• W4308394944 crossrefType "proceedings-article" @default.
• W4308394944 hasAuthorship W4308394944A5000978986 @default.
• W4308394944 hasAuthorship W4308394944A5007239425 @default.
• W4308394944 hasAuthorship W4308394944A5017326158 @default.
• W4308394944 hasAuthorship W4308394944A5022594161 @default.
• W4308394944 hasAuthorship W4308394944A5026163032 @default.
• W4308394944 hasAuthorship W4308394944A5044586794 @default.
• W4308394944 hasAuthorship W4308394944A5044692746 @default.
• W4308394944 hasAuthorship W4308394944A5045824886 @default.
• W4308394944 hasAuthorship W4308394944A5054697421 @default.
• W4308394944 hasAuthorship W4308394944A5061064382 @default.
• W4308394944 hasAuthorship W4308394944A5073060840 @default.
• W4308394944 hasAuthorship W4308394944A5075890039 @default.
• W4308394944 hasAuthorship W4308394944A5077456327 @default.
• W4308394944 hasAuthorship W4308394944A5077959964 @default.
• W4308394944 hasBestOaLocation W43083949441 @default.
• W4308394944 hasConcept C126322002 @default.
• W4308394944 hasConcept C143998085 @default.
• W4308394944 hasConcept C184235292 @default.
• W4308394944 hasConcept C197934379 @default.
• W4308394944 hasConcept C203014093 @default.
• W4308394944 hasConcept C2778472372 @default.
• W4308394944 hasConcept C535046627 @default.
• W4308394944 hasConcept C57074206 @default.
• W4308394944 hasConcept C60644358 @default.
• W4308394944 hasConcept C71924100 @default.
• W4308394944 hasConcept C86803240 @default.
• W4308394944 hasConcept C8891405 @default.
• W4308394944 hasConcept C95444343 @default.
• W4308394944 hasConceptScore W4308394944C126322002 @default.
• W4308394944 hasConceptScore W4308394944C143998085 @default.
• W4308394944 hasConceptScore W4308394944C184235292 @default.
• W4308394944 hasConceptScore W4308394944C197934379 @default.
• W4308394944 hasConceptScore W4308394944C203014093 @default.
• W4308394944 hasConceptScore W4308394944C2778472372 @default.
• W4308394944 hasConceptScore W4308394944C535046627 @default.
• W4308394944 hasConceptScore W4308394944C57074206 @default.
• W4308394944 hasConceptScore W4308394944C60644358 @default.
• W4308394944 hasConceptScore W4308394944C71924100 @default.
• W4308394944 hasConceptScore W4308394944C86803240 @default.
• W4308394944 hasConceptScore W4308394944C8891405 @default.
• W4308394944 hasConceptScore W4308394944C95444343 @default.
• W4308394944 hasLocation W43083949441 @default.
• W4308394944 hasOpenAccess W4308394944 @default.
• W4308394944 hasPrimaryLocation W43083949441 @default.
• W4308394944 hasRelatedWork W1966939585 @default.
• W4308394944 hasRelatedWork W1980199008 @default.
• W4308394944 hasRelatedWork W2374781999 @default.
• W4308394944 hasRelatedWork W2518309888 @default.
• W4308394944 hasRelatedWork W2527805684 @default.
• W4308394944 hasRelatedWork W2765194392 @default.
• W4308394944 hasRelatedWork W2885964272 @default.
• W4308394944 hasRelatedWork W3022645438 @default.
• W4308394944 hasRelatedWork W4236673861 @default.
• W4308394944 hasRelatedWork W4319661463 @default.
• W4308394944 isParatext "false" @default.
• W4308394944 isRetracted "false" @default.
• W4308394944 workType "article" @default.